All News

Drug costs in the United States are not consistently associated with their value or net health benefits.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Study offers insight into the evolution of global dissemination of hepatitis B virus genotypes D and A.

The FDA has approved updates to the labeling for hepatitis C virus (HCV) drug glecaprevir and pibrentasvir (Mavyret) to include new data from 2 clinical studies.

Officials with the FDA have approved a new treatment for 2 rare types of non-Hodgkin lymphoma of the skin.

The revised labeling for glecaprevir and pibrentasvir (Mavyret) includes data from clinical trials on the safety and efficacy of the treatment for HIV-1 coinfected patients and liver and kidney transplant recipients.

The FDA has approved several strengths of Apotex Inc.’s potassium chloride oral solution as the first generic drugs to receive a Competitive Generic Therapy designation.

Officials with the FDA have approved a new treatment for 2 rare types of non-Hodgkin lymphoma of the skin, relapsed or refractory mycosis fungoides and Sézary syndrome, after at least 1 prior systemic therapy.

Mogamulizumab-kpkc (Poteligeo, Kyowa Kirin) injection is indicated to treat adult patients with 2 types of non-Hodgkin lymphoma: relapsed or refractory mycosis fungoides or Sézary syndrome.

New formulation of gene-silencing drug may effectively treat amyotrophic lateral sclerosis.

A blood-based test to assess tumor mutational burden was recently discovered as being able to accurately identify patients with non–small cell lung cancer (NSCLC) who could benefit from checkpoint inhibitor treatment.

A healthy diet that includes physical activity and discourages alcohol consumption can significantly reduce overall cancer risk, as well as lower breast, prostate, and colorectal cancer risk.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

A recent study found that athletes with attention deficit hyperactivity disorder (ADHD) may need to be even more cautious in concussion prevention.

The agency has amended its list of drugs that contain the ingredient, which is used to treat high blood pressure and heart failure.

Officials with the FDA have updated the label of lumacaftor/ivacaftor (Orkambi, Vertex Pharmaceuticals), approving the treatment's use in children aged 2 to 5 years old.

Lumacaftor/ivacaftor (Orkambi, Vertex Pharmaceuticals) is the first drug approved to treat the underlying cause of cystic fibrosis in children aged 2 to 5 years old.

Medications with biosimilar and generic alternatives favored on pharmacy benefit manager’s national preferred formulary for 2019.

The FDA is encouraging the development of novel medication-assisted treatment drugs for individuals with opioid use disorder (OUD), while the first non-opioid medication indicated for the reduction of opioid withdrawal symptoms has been made available to the market.

The Affordable Care Act reduced financial strain for all low-income adults; however, the most significant reductions were seen in those living closest to the federal poverty line.

Interaction between hepatitis C virus and high alcohol consumption significantly limits patient survival.

In its latest report, the Institute for Clinical and Economic Review (ICER) evaluated the efficacy and value of newer targeted agents that treat moderate-to-severe plaque psoriasis compared with non-targeted therapies.

How you organize your pharmacy’s business to create significantly more success is what this article is all about.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Fenfluramine, a drug that was previously sold as an appetite suppressant before it was withdrawn from the market in 1997 over concerns about its link to heart valve problems, may have a new application.